AOD Peptide 99% Purity 5mg/10mg*10Vials Lyophilized Powder
386264-39-7
Industrial Grade
99%
China
KZY
5mg/10mg/vial;10 vials/box
2026-09-13
Retatrutide,Tirzepatide,Samaglutide
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial Referencesh-Oligopeptide-74 is a protein fragment which contains 16 amino acids and is produced synthetically to be identical to a fragment of the human protein, Somatropin. The fragment consists of the proper sequence of the 20 standard amino acids.Basic Info
-
Product Name:
AOD 9604
CAS No.:386264-39-7
Molecular Formula:C78H125N23O23S2
Molecular Weight:1817.0974
Categories:
Research-
Class:
Synthetic hGH fragment 177–191 (lipolytic peptide, 15-amino-acid cyclic)
Status:Research compound — Not FDA approved. Phase 2b obesity trials completed, not advanced.
Mechanism:A synthetic 15-amino-acid peptide (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, cyclized via Cys-Cys disulfide bond) derived from the C-terminal region (amino acids 177–191) of human growth hormone. AOD-9604 mimics the fat-metabolizing domain of hGH without stimulating IGF-1 or cell proliferation. It stimulates lipolysis via β3-adrenergic receptors and inhibits lipogenesis, producing selective fat reduction.
Activity note:AOD-9604 is a lipolytic peptide fragment, not a traditional receptor agonist. Functional lipolytic activity is observed at micromolar concentrations in adipocyte assays. Does not bind GHR.
Source:Ng FM, et al. J Endocrinol. 2000;165(3):595–605. Heffernan MA, et al. Am J Physiol Endocrinol Metab. 2000;279(3):E501–E507.DOI
Clinical Development:
References-
PubChem:Disclaimer:
AOD-9604 is NOT FDA-approved or EMA-approved. Phase 2b clinical trials for obesity were completed but the program was not advanced to Phase 3. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Samaglutide
-
Location:
Room 205, Sanyuanli Avenue, Baiyun District, Guangzhou City
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
